A Phase 2a, Dose-Escalation, Open-Label Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host Disease
Phase of Trial: Phase II
Latest Information Update: 10 Dec 2017
At a glance
- Drugs KD 025 (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Kadmon Corporation
- 10 Dec 2017 Results published in a Kadmon Pharmaceuticals media release.
- 01 Nov 2017 According to a Kadmon Holdings media release, initial results from this trial will be presented at the 59th American Society of Hematology (ASH) Annual Meeting.
- 03 Aug 2017 According to a Kadmon media release, additional study results submitted for presentation at upcoming scientific conferences.